Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
Page 2

The organizers of the program hopes for the outcome of the project to have a substantial impact bioequivalence policy development for generic orally inhaled products.

Furthermore, the initiatives included under this funding opportunity announcement also intends to achieve the following objectives:

a) Develop a quality-by-design tool that could be utilized to improve the performance of orally inhaled drugs during the product development phase.

b) Determine accurate dose predictions.

c) Set clinical relevant aerodynamic particle size distribution specifications to ensure product quality, for these drug/device combination products.

To support these initiatives, the USFDA is ready to administer funds in the amount of $150,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The Department of Health and Human Services, the mother agency funding the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program, is the nation's leading agency for protecting the health of all Americans and providing fundamental human services to all.

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

Academic-Community Partnership Conference Series Program
In line with this mission, the National Institutes of Health has recently formed a partnership with the The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to establish the Academic-Community Partnership Conference Series Program wherein both agencies seek to solicit grant application that intend to conduct health disparities-related meetings, workshops, symposiums.

---

National Institutes of Health funds the Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults
The National Institutes of Health has recently established a program entitled Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults wherein they intend to kick-off research studies that will create, implement, and evaluate both old and new interventions that are geared towards improving adherence to medical and behavioral regimens for HIV-positive adolescents which are 11 to 21 years old and adults who are 21 to 24 years old.

---

National Institutes of Health: Expanding the Encyclopedia of DNA Elements in Human and Model Organisms
The National Institutes of Health, in cooperation with the National Human Genome Research Institute, has established a funding opportunity to support the Expanding the Encyclopedia of DNA Elements in Human and Model Organisms project.

---